Appel Tobias Manuel, Mojica María Fernanda, De La Cadena Elsa, Pallares Christian José, Radice Marcela A, Castañeda-Méndez Paulo, Jaime-Villalón Diego A, Gales Ana C, Munita José M, Villegas María Virginia
Grupo de Resistencia Antimicrobiana y Epidemiología Hospitalaria (RAEH), Universidad El Bosque, Bogotá 110121, Colombia.
Grupo de Resistencia Bacteriana, Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Cali 760031, Colombia.
Antibiotics (Basel). 2020 Feb 5;9(2):62. doi: 10.3390/antibiotics9020062.
: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which has shown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. : The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 and October 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. : CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% of Enterobacterales being susceptible. : The results of this study underline the potential therapeutic role of CZA in Latin America.
拉丁美洲已报告肠杆菌科细菌对第三代头孢菌素和碳青霉烯类药物的高耐药率。头孢他啶/阿维巴坦（CZA）是第三代头孢菌素与非β-内酰胺β-内酰胺酶抑制剂的组合，已显示出对产生A、C和D类β-内酰胺酶的分离株具有活性。在此，我们评估了CZA和对照药物对拉丁美洲肠杆菌科临床分离株的活性。
对2016年1月至2017年10月期间从阿根廷、巴西、智利、哥伦比亚和墨西哥收集的肠杆菌科临床分离株评估了CZA和对照药物的活性。评估了一个特定的表型亚组。碳青霉烯类药物不敏感（CNS）表型定义为对厄他培南的最低抑菌浓度（MIC）≥1mg/L的任何分离株。
CZA对所有分离株的95.8%和CNS分离株的77.5%有活性。磷霉素（FOS）和替加环素（TGC）是第二活性最高的抗生素，肠杆菌科细菌的93.4%对其敏感。
本研究结果强调了CZA在拉丁美洲的潜在治疗作用。
